JAMES MICHAEL C 4

What Happened

• James Michael, a director of Guided Therapeutics, received a derivative award of 110,000 shares on March 10, 2026. The award is reported at an acquisition price of $0.00 (no cash paid). This is a grant/compensation award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-03-10; transaction type/code: Award/Grant (A); shares: 110,000; price: $0.00.
• Vesting: One-fourth (27,500 shares) vested on March 10, 2026; remaining shares vest monthly beginning June 10, 2026, subject to continued service, fully vesting on March 10, 2029 (per footnote).
• Shares owned after the transaction: not specified in the filing.
• Filing timeliness: Report filed 2026-04-07 for a 2026-03-10 transaction — this is a delayed Form 4 filing (late disclosure), which reduces immediacy of public disclosure.

Context

• This grant is a compensation award (likely restricted stock/RSUs style given the vesting schedule). Awards at $0 generally reflect compensation rather than a market purchase; they do not by themselves indicate a buy/sell market signal.
• For retail investors, note that vested shares may be sellable depending on company policies, but this filing records only the grant and vesting schedule, not any sale.